WCM
UTHR icon

Waterstone Capital Management’s United Therapeutics UTHR Stock Holding History

Waterstone Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-130,913
Closed -$8.62M – 35
2013
Q2 		$8.62M Buy
+130,913
New +$8.43M 0.77% 20

Other funds holding UTHR

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Waterstone Capital Management's UTHR Position: Q3 2013 in Review

Waterstone Capital Management sold out of United Therapeutics (UTHR) in Q3 2013, closing a stake of 130,913 shares — an estimated $8.62M sold.

Waterstone Capital Management first reported a position in UTHR in Q2 2013 and held it in 1 quarter. The position peaked at $8.62M in Q2 2013. 293 funds tracked by Wall St. Rank hold UTHR as of Q3 2013.

  • Waterstone Capital Management reported no remaining United Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Waterstone Capital Management sold 130,913 United Therapeutics shares in Q3 2013, an estimated $8.62M.
  • Waterstone Capital Management first reported a position in United Therapeutics in Q2 2013 and held it in 1 quarter.
  • Waterstone Capital Management's United Therapeutics position peaked at $8.62M in Q2 2013.
  • 293 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2013.

Based on Waterstone Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.